{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:10:30Z","timestamp":1791443430911,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtos.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:01:40Z","timestamp":1750680100000},"page":"97-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Moxifloxacin-resistant and moxifloxacin-susceptible Staphylococcus aureus Keratitis: Outcomes from a 10-year retrospective study"],"prefix":"10.1016","volume":"38","author":[{"given":"Raven","family":"Diacou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan Bir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.Q.","family":"Shanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Jhanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2025.06.008_bib1","article-title":"Paradox of complex diversity: challenges in the diagnosis and management of bacterial keratitis","author":"Singh","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2025.06.008_bib2","doi-asserted-by":"crossref","DOI":"10.1086\/314056","article-title":"Mechanisms of action and resistance of older and newer fluoroquinolones","volume":"31","author":"Hooper","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.jtos.2025.06.008_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"issue":"6 SUPPL. 1","key":"10.1016\/j.jtos.2025.06.008_bib4","article-title":"In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone","volume":"50","author":"Stroman","year":"2005","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2025.06.008_bib5","article-title":"Topical ocular delivery of fluoroquinolones","volume":"10","author":"Pawar","year":"2013","journal-title":"Expet Opin Drug Deliv"},{"issue":"2 SUPPL. 2","key":"10.1016\/j.jtos.2025.06.008_bib6","article-title":"Fluoroquinolones: mechanism of action, classification, and development of resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2025.06.008_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1751-7915.2008.00063.x","article-title":"Mechanism of action of and resistance to quinolones","volume":"2","author":"F\u00e0brega","year":"2009","journal-title":"Microb Biotechnol"},{"issue":"6 SUPP","key":"10.1016\/j.jtos.2025.06.008_bib8","article-title":"Contact lens-associated microbial keratitis","volume":"71","author":"Moriyama","year":"2009","journal-title":"Arq Bras Oftalmol"},{"issue":"2 SUPPL. 2","key":"10.1016\/j.jtos.2025.06.008_bib9","article-title":"Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones","volume":"49","author":"Hwang","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2025.06.008_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9394(03)00294-0","article-title":"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates","volume":"136","author":"Kowalski","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.06.008_bib11","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S1666","article-title":"Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections","author":"Miller","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2025.06.008_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/00055735-200408000-00007","article-title":"Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections","volume":"15","author":"Mah","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2025.06.008_bib13","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20175901","article-title":"Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes","volume":"50","author":"Silva","year":"2017","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"10.1016\/j.jtos.2025.06.008_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/microorganisms12040649","article-title":"Topical antibiotic therapy in the ocular environment: the benefits of using moxifloxacin eyedrops","volume":"12","author":"Drago","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.jtos.2025.06.008_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2020.03.017","article-title":"Methicillin-resistant Staphylococcus aureus keratitis: initial treatment, risk factors, clinical features, and treatment outcomes","volume":"214","author":"Durrani","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2025.06.008_bib16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jamaophthalmol.2015.3888","article-title":"Antibiotic resistance among ocular pathogens in the United States five-year results from the antibiotic resistance monitoring in ocular microorganisms (ARMOR) surveillance study","volume":"133","author":"Asbell","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2025.06.008_bib17","article-title":"Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009\u20132016)","volume":"11","author":"Thomas","year":"2019","journal-title":"Clin Optom"},{"issue":"2","key":"10.1016\/j.jtos.2025.06.008_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s40123-021-00449-9","article-title":"A systematic review of multi-decade antibiotic resistance data for ocular bacterial pathogens in the United States","volume":"11","author":"Bispo","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"10.1016\/j.jtos.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/ICO.0000000000000431","article-title":"Antibiotic resistance in the treatment of staphylococcus aureus keratitis: a 20-year review","volume":"34","author":"Chang","year":"2015","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.jtos.2025.06.008_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2012.11.013","article-title":"Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial","volume":"120","author":"Sharma","year":"2013","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2025.06.008_bib21","article-title":"Ophthalmic infections and their anti-infective challenges","volume":"50","author":"Alfonso","year":"2005","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.06.008_bib22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1167\/iovs.12-11246","article-title":"Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis","volume":"54","author":"Oldenburg","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.jtos.2025.06.008_bib23","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.ophtha.2006.12.011","article-title":"Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial","volume":"114","author":"Constantinou","year":"2007","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jtos.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1167\/iovs.09-4638","article-title":"Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis","volume":"51","author":"Sueke","year":"2010","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.jtos.2025.06.008_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/ICO.0b013e3181ca2ba3","article-title":"Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers","volume":"29","author":"Shah","year":"2010","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.jtos.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ophtha.2012.11.013","article-title":"Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial","volume":"120","author":"Sharma","year":"2013","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2025.06.008_bib27","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00417-023-06362-0","article-title":"A comparison of antimicrobial regimen outcomes and antibiogram development in microbial keratitis: a prospective cohort study in Alexandria, Egypt","volume":"262","author":"Nayel","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2025.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-02039-1","article-title":"Cationic polyelectrolyte nanocapsules of moxifloxacin for microbial keratitis therapy: development, characterization, and pharmacodynamic study","volume":"22","author":"Mohan","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jtos.2025.06.008_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112113","article-title":"Hydroxypropyl methacrylamide-based copolymeric nanoparticles loaded with moxifloxacin as a mucoadhesive, cornea-penetrating nanomedicine eye drop with enhanced therapeutic benefits in bacterial keratitis","volume":"208","author":"Ch","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"12","key":"10.1016\/j.jtos.2025.06.008_bib30","doi-asserted-by":"crossref","DOI":"10.18240\/ijo.2019.12.13","article-title":"Treating with besifloxacin for acute bacterial conjunctivitis: a meta-analysis","volume":"12","author":"Wang","year":"2019","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2025.06.008_bib31","article-title":"Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis","volume":"4","author":"Comstock","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.06.008_bib32","article-title":"Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study","volume":"31","author":"Schechter","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.jtos.2025.06.008_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s40123-016-0046-6","article-title":"Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections","volume":"5","author":"Mah","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2025.06.008_bib34","article-title":"Effectiveness, tolerability and safety of azithromycin 1% in DuraSite\u00ae for acute bacterial conjunctivitis","volume":"4","author":"McLean","year":"2010","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1016\/j.jtos.2025.06.008_bib35","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1128\/AAC.00289-11","article-title":"Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin","volume":"55","author":"Truong-Bolduc","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jtos.2025.06.008_bib36","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1128\/AAC.45.11.3076-3083.2001","article-title":"Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance","volume":"45","author":"Entenza","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jtos.2025.06.008_bib37","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/ICO.0000000000002414","article-title":"Efficacy of a novel ophthalmic antimicrobial drug combination toward a large panel of Staphylococcus aureus clinical ocular isolates from around the world","volume":"39","author":"Laskey","year":"2020","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2025.06.008_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/ICO.0000000000001417","article-title":"Bacterial keratitis: isolated organisms and antibiotic resistance patterns in San Francisco","volume":"37","author":"Peng","year":"2018","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.jtos.2025.06.008_bib39","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/cid\/cis189","article-title":"Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis","volume":"54","author":"Lalitha","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jtos.2025.06.008_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/ICO.0000000000002803","article-title":"Outcomes of microbial keratitis cases resistant to antimicrobials in Sydney, Australia","volume":"41","author":"Cabrera-Aguas","year":"2022","journal-title":"Cornea"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:58:56Z","timestamp":1764755936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"alternative-id":["S1542012425000862"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.06.008","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moxifloxacin-resistant and moxifloxacin-susceptible Staphylococcus aureus Keratitis: Outcomes from a 10-year retrospective study","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}